Crucell to Release First Quarter 2010 Results on Tuesday May 11, 2010
(Thomson Reuters ONE) -
Leiden, the Netherlands (May 4, 2010) - Dutch biopharmaceutical company Crucell
N.V. (NYSE Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced that it
will release its financial results for the first quarter 2010 on Tuesday May
11, 2010 at 07:45 Central European Time (CET).
At 14:00 Central European Time (CET), Crucell's management will conduct a
conference call, which will also be webcast. To participate in the conference
call, please call one of the following telephone numbers 15 minutes prior to the
event:
+44 20 7138 0845 for the UK;
+1 212 444 0896 for the US; and
+3120 201 5469 for the Netherlands
Following a presentation of the results, the lines will be opened for a question
and answer session.
The live audio webcast can be accessed via the homepage of Crucell's website at
www.crucell.com and will be archived and available for replay following the
event.
About Crucell
Crucell N.V. (NYSE Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a global
biopharmaceutical company focused on research development, production and
marketing of vaccines, proteins and antibodies that prevent and/or treat
infectious diseases. In 2009 alone, Crucell distributed more than 115 million
vaccine doses in more than 100 countries around the world, with the fast
majority of doses going to developing countries. Crucell is one of the major
suppliers of vaccines to UNICEF and the developing world. Crucell was the first
manufacturer to launch a fully-liquid pentavalent vaccine called Quinvaxem(®).
Quinvaxem(®) protects against five important childhood diseases and over 130
million doses have been sold since its launch in 2006 in more than 50 GAVI
countries. Through Quinvaxem(®) and its innovation, Crucell has become a major
partner in protecting children in developing countries. Crucell's core portfolio
also includes a vaccine against hepatitis B and a virosome-adjuvanted vaccine
against influenza. Crucell also markets travel vaccines, such as an oral
anti-typhoid vaccine, an oral cholera vaccine and the only aluminum-free
hepatitis A vaccine on the market. The Company has a broad development pipeline,
with several product candidates based on its unique PER.C6(®) production
technology. The Company licenses its PER.C6(®) technology and other technologies
to the biopharmaceutical industry. Important partners and licensees include
Johnson & Johnson, DSM Biologics, sanofi-aventis, Novartis, Wyeth, GSK, CSL and
Merck & Co. Crucell is headquartered in Leiden, the Netherlands, with
subsidiaries in Argentina, China, Italy, Korea, Spain, Sweden, Switzerland, UK
and the USA. The Company employs over 1200 people. For more information, please
visit www.crucell.com
Forward-looking statements
This press release contains forward-looking statements that involve inherent
risks and uncertainties. We have identified certain important factors that may
cause actual results to differ materially from those contained in such
forward-looking statements. For information relating to these factors please
refer to our Form 20-F, as filed with the US Securities and Exchange Commission
on April 7, 2010, in the section entitled 'Risk Factors'. The Company prepares
its financial statements under International Financial Reporting Standards
(IFRS).
Financial Calendar
4 June 2010 Annual General Meeting of Shareholders
17 August 2010 Q2 Results 2010
9 November 2010 Q3 Results 2010
15 February 2011 Q4/FY Results 2010
For further information please contact Crucell:
Oya Yavuz
Vice President Corporate Communications & Investor Relations
Tel. +31 (0)71 519 7064
www.crucell.com
[HUG#1411559]
PDF file: http://hugin.info/132631/R/1411559/363968.pdf
Unternehmensinformation / Kurzprofil:
Datum: 04.05.2010 - 13:01 Uhr
Sprache: Deutsch
News-ID 20220
Anzahl Zeichen: 0
contact information:
Town:
Leiden
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 207 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Crucell to Release First Quarter 2010 Results on Tuesday May 11, 2010"
steht unter der journalistisch-redaktionellen Verantwortung von
Crucell N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
